Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Celcuity Inc (NQ: CELC )

15.77 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1
Open 15.77
Bid (Size) 15.85 (2)
Ask (Size) 21.49 (1)
Prev. Close 15.77
Today's Range 15.77 - 15.77
52wk Range 8.389 - 22.04
Shares Outstanding 30,453,120
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
CELC Stock Earnings: Celcuity Beats EPS for Q4 2023
CELC stock results show that Celcuity beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Recap: Celcuity Q4 Earnings
Via Benzinga

Performance

YTD
+6.70%
+6.70%
1 Month
-9.99%
-9.99%
3 Month
+7.72%
+7.72%
6 Month
+51.63%
+51.63%
1 Year
+60.92%
+60.92%

More News

Read More
Earnings Scheduled For March 27, 2024
Via Benzinga
Celcuity Earnings Preview
Via Benzinga
A Preview Of Celcuity's Earnings
Via Benzinga
Preview: Celcuity's Earnings
Via Benzinga
A Preview Of Celcuity's Earnings
Via Benzinga
Celcuity's Earnings: A Preview
Via Benzinga
Earnings Scheduled For November 13, 2023
Via Benzinga
Celcuity Inc. Announces $50 Million Private Placement
Via ACCESSWIRE
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
The 7 Best Short-Squeeze Stocks to Buy Now: September 2023
Via InvestorPlace
7 Short-Squeeze Stocks That Actually Might Make Sense
Via InvestorPlace
10 Short Squeeze Stocks To Watch: Yellow Corporation, Getty Images, Tupperware And More
Via Benzinga
Celcuity Set to Join Russell 2000 and 3000 Indexes
Via ACCESSWIRE
Celcuity to Participate in Upcoming Craig-Hallum and Jefferies Investor Conferences
Via ACCESSWIRE
Celcuity Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Updates
Via ACCESSWIRE
Celcuity Presents Updated Results from Phase 1b Study of Gedatolisib in Treatment-Naïve Patients at the 2023 ESMO Breast Cancer Annual Congress
Via ACCESSWIRE
Celcuity Inc. Schedules Release of First Quarter 2023 Financial Results and Webcast/Conference Call
Via ACCESSWIRE
Celcuity to Present Updated Results for Treatment-Naïve Patients from Phase 1b Study of Gedatolisib at the 2023 ESMO Breast Cancer Annual Congress
Via ACCESSWIRE
Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Gynecological Cancer Models at AACR Annual Meeting 2023
Via ACCESSWIRE
Celcuity to Participate in 22nd Annual Needham Virtual Healthcare Conference
Via ACCESSWIRE
Celcuity Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Via ACCESSWIRE
Earnings Scheduled For March 23, 2023
Via Benzinga
Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2022 Financial Results and Webcast/Conference Call
Via ACCESSWIRE
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.